5:57 PM
 | 
Jan 24, 2013
 |  BC Extra  |  Clinical News

Genomic Health reports cost-effectiveness data for colon cancer assay

Genomic Health Inc. (NASDAQ:GHDX) reported data from a cost-effectiveness analysis of 141 patients with stage II colon cancer showing that physicians reduced the number of recommendations for adjuvant chemotherapy by 22% after receiving...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >